New drug LAD191 takes first step: is it safe for people?
NCT ID NCT06488209
First seen Nov 25, 2025 · Last updated May 21, 2026 · Updated 19 times
Summary
This early-stage study tested the safety of a new drug called LAD191 in 69 adults—some healthy and some with an autoimmune disease. Researchers measured side effects, how the drug moves through the body, and whether it triggers an immune response. The goal was not to treat the disease but to gather essential safety data before larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Doral Medical Research
Miami, Florida, 33165, United States
-
ICON Early Phase Services, LLC
San Antonio, Texas, 78209, United States
-
Jennifer Parish, MD
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.